BMS-094 (f/k/a INX-189, a/k/a BMS-986094) is in trouble
BMY's strategy was (and still is) to combo test INX-189 at/or below the 200mg. dose and hope the nuke can provide a strong enough resistance profile without crapping out on safety (aka IDX-184). Any lack of potency testing INX-189 at lower therapeutic doses (in theory) could be overcome by the other classes of drugs within the combination. IMO BMY knew INX-189 was a impaired asset before signing off on the deal. GILD acquiring VRUS, along with the scarcity value within the nuke class, forced their hand on this deal.
INHX claimed they were waiting on regulatory approval to test the 300mg. dose of INX-189 before they were bought by BMY. As I previously pointed out this was only posturing to draw in a bidder. It was clear to me this drug was borderline unsafe and BMY knew it just as well. They just didn't have any other options.
Market Data 
Markets 
AI
